

In the Claims:

Please withdraw from consideration claims 1-41, 45-46 and 58-112 without prejudice to the filing of any divisional, continuation, or continuation-in-part application.

Please amend the claims as follows:

A2
42. (Amended) An ANT1 adenine nucleotide translocator polypeptide produced by a method comprising culturing a host cell comprising a recombinant expression construct comprising at least one regulated promoter operably linked to a nucleic acid encoding the ANT1 adenine nucleotide translocator polypeptide.

B6
43. (Amended) An isolated human ANT1 adenine nucleotide translocator polypeptide.

44. (Amended) The isolated polypeptide of claim 43 wherein the human ANT1 adenine nucleotide translocator polypeptide is recombinant ANT1 or a variant or fragment thereof.

A3
47. (Amended) An isolated human ANT1 adenine nucleotide translocator fusion protein comprising an ANT1 adenine translocator polypeptide fused to at least one additional polypeptide sequence.

A4
51. (Amended) An isolated human ANT1 adenine nucleotide translocator fusion protein comprising an ANT1 adenine translocator polypeptide fused to at least one additional polypeptide sequence cleavable by a protease, said ANT1 adenine nucleotide translocator polypeptide being separable from the fusion protein by cleavage with the protease.